(Q24203870)

26 October 2023

Andrew Booth

4

Andrew

Booth

1 reference

26 October 2023

Kareem Salhiyyah

1

Kareem

Salhiyyah

1 reference

26 October 2023

Eshan Senanayake

series ordinal

2

author given names

Eshan

author last names

Senanayake

1 reference

26 October 2023

Mohammed Abdel-Hadi

series ordinal

3

author given names

Mohammed

author last names

Abdel-Hadi

1 reference

Cochrane Database of Systematic Reviews

26 October 2023

publication date

18 January 2012

0 references

published in

0 references

cites work

Venous thrombosis from air travel: the LONFLIT3 study--prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

A randomized trial of iloprost in patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Does pentoxifylline prolong the walking distance in exercised claudicants? A placebo-controlled double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Intermittent claudication: a double-blind crossover trial of pentoxifylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Effects of Flunarizine and Pentoxifylline on Walking Distance and Blood Rheology in Claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Another look at the pentoxifylline efficacy data for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Dose-response effects of pentoxifylline on erythrocyte filterability: clinical and animal model studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

The effects of prostaglandin E-1 in patients with intermittent claudication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Pentoxifylline treatment in patients with occlusive peripheral arterial disease. Circulatory changes and effects on prostaglandin synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

A therapeutic comparison between hemodilution and pentoxifylline in arterial obstructive disease. An objective assessment by quantitative Doppler sonography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Endovascular stents for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Pentoxifylline for intermittent claudication. A critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

A rational approach to diagnosis and treatment of intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Angioplasty (versus non surgical management) for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Pharmacological management of intermittent claudication: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Prostanoids for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Exercise for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Antiplatelet agents for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

A comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: results of double-blind study versus vasodilator-nylidrin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

A comparison of cilostazol and pentoxifylline for treating intermittent claudication

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

The effect of withdrawal of drugs treating intermittent claudication

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Pharmacological reduction of the systemically damaging effects of local ischaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Incidence and management of intermittent claudication in primary care in The Netherlands

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Leukocyte activation study during occlusive arterial disease of the lower limb: effect of pentoxifylline infusion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Pentoxifylline in the treatment of intermittent claudication of the lower limbs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Studies of the clinical pharmacology and therapeutic efficacy of pentoxifylline in peripheral obstructive arterial disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Influence of pentoxifylline on muscle tissue oxygen tension (pO2) of patients with intermittent claudication before and after pedal ergometer exercise

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Effects of pentoxifylline on severe intermittent claudication

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Quinapril--a new angiotensin-converting enzyme inhibitor: an overview

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Effects of indobufen and pentoxifylline on walking capacity and hemostasis in patients with intermittent claudication: results of six months of treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Does oxpentifylline (‘Trental’) have a place in the treatment of intermittent claudication?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Controlled clinical trial on the efficacy and safety of oral sulodexide in patients with peripheral occlusive arterial disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

Propionyl-L-Carnitine versus Pentoxifylline : Improvement in Walking Capacity in Patients with Intermittent Claudication

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005262.PUB2

7 January 2021

10.1002/14651858.CD005262.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_sobik7dl7bef3l3obutonon63q

0 references